Objective: Resilience is the ability to bounce back from stressful events using individual and environmental resources. The online intervention program, MoVemEnT, which includes mindfulness training and emotion regulation, was developed to enhance resilience among young adults. Methods: Persons without current medical or psychiatric diseases, aged 20–40 years, were recruited. Ninety-six participants were randomly assigned to either the intervention group or a waiting list control (WLC) group, with 45 participants per group completing the program. Results: Results demonstrated significant improvements in the intervention group in measures of emotion regulation (Difficulties in Emotion Regulation Scale, DERS) and clinical symptoms of depression (Center for Epidemiological Studies-Depression Scale, CES-D) and anxiety (Generalized Anxiety Disorder-7) compared to the WLC group (all p<0.05). Correlation analyses indicated that improvements in DERS scores were associated with enhanced resilience, as measured by the Korean Resilience Quotient-53 (KRQ-53) and reduced CES-D scores. Reduction in DERS scores can reduce depressive symptoms (CES-D) through direct and indirect pathways via an increase in KRQ-53, according to mediation analyses. Conclusion Our findings reported positive effects of the MoVemEnT program, which includes short videos and brief homework assignments, on resilience in young adults. This study suggests that online intervention programs could offer an opportunity to simultaneously improve general mental health among a large population and may help reduce the burden of face-to-face psychological interventions.

Ketone bodies produced by sodium-glucose cotransporter 2 (SGLT2) inhibitors can be advantageous, providing an efficient and stable energy source for the brain and muscles. However, in patients with diabetes, ketogenesis induced by SGLT2 inhibitors may be harmful, potentially resulting in severe diabetic ketoacidosis (DKA). During fasting, ketone body production serves as an alternative and efficient energy source for the brain by utilizing stored fat, promoting mental clarity, and reducing dependence on glucose. The concurrent use of SGLT2 inhibitors during perioperative fasting may further elevate the risk of euglycemic DKA. We describe a case of DKA that occurred during perioperative fasting in a patient receiving empagliflozin, an SGLT2 inhibitor. This case underscores the importance of recognizing the potential risk of DKA in patients with diabetes using SGLT2 inhibitors during perioperative fasting.

Background: The novel sodium-glucose cotransporter-2 (SGLT2) inhibitor enavogliflozin effectively lowers glycosylated hemoglobin levels and body weights without the increased risk of serious adverse events; however, the long-term clinical benefits of enavogliflozin in terms of cardiovascular and renal outcomes have not been investigated. Methods: This study is an investigator-initiated, multicenter, randomized, pragmatic, open-label, active-controlled, non-inferiority trial. Eligible participants are adults (aged ≥19 years) with type 2 diabetes mellitus (T2DM) who have a history of, or are at risk of, cardiovascular disease. A total of 2,862 participants will be randomly assigned to receive either enavogliflozin or other SGLT2 inhibitors with proven cardiorenal benefits, such as dapagliflozin or empagliflozin. The primary endpoint is the time to the first occurrence of a composite of major adverse cardiovascular or renal events (Clinical Research Information Service registration number: KCT0009243). Conclusion This trial will determine whether enavogliflozin is non-inferior to dapagliflozin or empagliflozin in terms of cardiorenal outcomes in patients with T2DM and cardiovascular risk factors. This study will elucidate the role of enavogliflozin in preventing vascular complications in patients with T2DM.

Purpose: The Korean Cancer Study Group (KCSG) is a nationwide cancer clinical trial group dedicated to advancing investigator-initiated trials (IITs) by conducting and supporting clinical trials. This study aims to review IITs conducted by KCSG and quantitatively evaluate the survival and financial benefits of IITs for patients. Materials and Methods: We reviewed IITs conducted by KCSG from 1998 to 2023, analyzing progression-free survival (PFS) and overall survival (OS) gains for participants. PFS and OS benefits were calculated as the difference in median survival times between the intervention and control groups, multiplied by the number of patients in the intervention group. Financial benefits were assessed based on the cost of investigational products provided. Results: From 1998 to 2023, KCSG conducted 310 IITs, with 133 completed and published. Of these, 21 were included in the survival analysis. The analysis revealed that 1,951 patients in the intervention groups gained a total of 2,558.4 months (213.2 years) of PFS and 2,501.6 months (208.5 years) of OS, with median gains of 1.31 months in PFS and 1.58 months in OS per patient. When analyzing only statistically significant results, PFS and OS gain per patients was 1.69 months and 3.02 months, respectively. Investigational drug cost analysis from six available IITs indicated that investigational products provided to 252 patients were valued at 10,400,077,294 won (approximately 8,046,481 US dollars), averaging about 41,270,148 won (approximately 31,930 US dollars) per patient. Conclusion Our findings, based on analysis of published research, suggest that IITs conducted by KCSG led to survival benefits for participants and, in some studies, may have provided financial benefits by providing investment drugs.

Purpose: This multicenter, open-label, phase II trial evaluated the efficacy and safety of bortezomib combined with dexamethasone for the treatment of relapsed/refractory cutaneous T-cell lymphoma (CTCL) in previously treated patients across 14 institutions in South Korea. Materials and Methods: Between September 2017 and July 2020, 29 patients with histologically confirmed CTCL received treatment, consisting of eight 4-week cycles of induction therapy followed by maintenance therapy, contingent upon response, for up to one year. The primary endpoint was the proportion of patients achieving an objective global response. Results: Thirteen of the 29 patients (44.8%) achieved an objective global response, including two complete responses. The median progression-free survival (PFS) was 5.8 months, with responders showing a median PFS of 14.0 months. Treatment-emergent adverse events were generally mild, with a low incidence of peripheral neuropathy and hematologic toxicities. Despite the trend toward shorter PFS in patients with higher mutation burdens, genomic profiling before and after treatment showed no significant emergence of new mutations indicative of disease progression. Conclusion This study supports the use of bortezomib and dexamethasone as a viable and safe treatment option for previously treated CTCL, demonstrating substantial efficacy and manageability in adverse effects. Further research with a larger cohort is suggested to validate these findings and explore the prognostic value of mutation profiles.

Objective: Resilience is the ability to bounce back from stressful events using individual and environmental resources. The online intervention program, MoVemEnT, which includes mindfulness training and emotion regulation, was developed to enhance resilience among young adults. Methods: Persons without current medical or psychiatric diseases, aged 20–40 years, were recruited. Ninety-six participants were randomly assigned to either the intervention group or a waiting list control (WLC) group, with 45 participants per group completing the program. Results: Results demonstrated significant improvements in the intervention group in measures of emotion regulation (Difficulties in Emotion Regulation Scale, DERS) and clinical symptoms of depression (Center for Epidemiological Studies-Depression Scale, CES-D) and anxiety (Generalized Anxiety Disorder-7) compared to the WLC group (all p<0.05). Correlation analyses indicated that improvements in DERS scores were associated with enhanced resilience, as measured by the Korean Resilience Quotient-53 (KRQ-53) and reduced CES-D scores. Reduction in DERS scores can reduce depressive symptoms (CES-D) through direct and indirect pathways via an increase in KRQ-53, according to mediation analyses. Conclusion Our findings reported positive effects of the MoVemEnT program, which includes short videos and brief homework assignments, on resilience in young adults. This study suggests that online intervention programs could offer an opportunity to simultaneously improve general mental health among a large population and may help reduce the burden of face-to-face psychological interventions.

Objective: Resilience is the ability to bounce back from stressful events using individual and environmental resources. The online intervention program, MoVemEnT, which includes mindfulness training and emotion regulation, was developed to enhance resilience among young adults. Methods: Persons without current medical or psychiatric diseases, aged 20–40 years, were recruited. Ninety-six participants were randomly assigned to either the intervention group or a waiting list control (WLC) group, with 45 participants per group completing the program. Results: Results demonstrated significant improvements in the intervention group in measures of emotion regulation (Difficulties in Emotion Regulation Scale, DERS) and clinical symptoms of depression (Center for Epidemiological Studies-Depression Scale, CES-D) and anxiety (Generalized Anxiety Disorder-7) compared to the WLC group (all p<0.05). Correlation analyses indicated that improvements in DERS scores were associated with enhanced resilience, as measured by the Korean Resilience Quotient-53 (KRQ-53) and reduced CES-D scores. Reduction in DERS scores can reduce depressive symptoms (CES-D) through direct and indirect pathways via an increase in KRQ-53, according to mediation analyses. Conclusion Our findings reported positive effects of the MoVemEnT program, which includes short videos and brief homework assignments, on resilience in young adults. This study suggests that online intervention programs could offer an opportunity to simultaneously improve general mental health among a large population and may help reduce the burden of face-to-face psychological interventions.

Ketone bodies produced by sodium-glucose cotransporter 2 (SGLT2) inhibitors can be advantageous, providing an efficient and stable energy source for the brain and muscles. However, in patients with diabetes, ketogenesis induced by SGLT2 inhibitors may be harmful, potentially resulting in severe diabetic ketoacidosis (DKA). During fasting, ketone body production serves as an alternative and efficient energy source for the brain by utilizing stored fat, promoting mental clarity, and reducing dependence on glucose. The concurrent use of SGLT2 inhibitors during perioperative fasting may further elevate the risk of euglycemic DKA. We describe a case of DKA that occurred during perioperative fasting in a patient receiving empagliflozin, an SGLT2 inhibitor. This case underscores the importance of recognizing the potential risk of DKA in patients with diabetes using SGLT2 inhibitors during perioperative fasting.

A schwannoma is a benign soft tissue tumor derived from Schwann cells of the nerve sheath. The lateral femoral cutaneous nerve is a sensory nerve originating from the second and third lumbar vertebra nerve roots, passing under the inguinal ligament and dividing into anterior and posterior branches. The anterior branch which is a major division and the main nerve that causes meralgia paresthetica supplies the knee joint from the anterior thigh. In addition, the posterior branch supplies the lateral thigh at the greater trochanter level.This paper reports the case of a 52-year-old woman with a very rare schwannoma in the terminal twig of posterior branch of the lateral femoral cutaneous nerve of right thigh protruded through the fascia lata with literatures review.

Purpose: Developmentally regulated GTP-binding protein 2 (DRG2) regulates microtubule dynamics and G2/M arrest during docetaxel treatment. Poly ADP-ribose polymerase (PARP) acts as an important repair system for DNA damage caused by docetaxel treatment. This study investigated whether DRG2 expression affects response to PARP inhibitors (olaparib) using prostate cancer cell lines PC3, DU145, LNCaP-FGC, and LNCaP-LN3. Materials and Methods: The cell viability and DRG2 expression levels were assessed using colorimetric-based cell viability assay and western blot. Cells were transfected with DRG2 siRNA, and pcDNA6/V5-DRG2 was used to overexpress DRG2. Flow cytometry was applied for cell cycle assay and apoptosis analysis using the Annexing V cell death assay. Results: The expression of DRG2 was highest in LNCaP-LN3 and lowest in DU145 cells. Expressions of p53 in PC3, DU145, and the two LNCaP cell lines were null-type, high-expression, and medium-expression, respectively. In PC3 (DRG2 high, p53 null) cells, docetaxel increased G2/M arrest without apoptosis; however, subsequent treatment with olaparib promoted apoptosis. In DU145 and LNCaP-FGC (DRG2 low), docetaxel increased sub-G1 but not G2/M arrest and induced apoptosis, whereas olaparib had no additional effect. In LNCaP-LN3 (DRG2 high, p53 wild-type), docetaxel increased sub-G1 and G2/M arrest, furthermore olaparib enhanced cell death. Docetaxel and olaparib combination treatment had a slight effect on DRG2 knockdown PC3, but increased apoptosis in DRG2-overexpressed DU145 cells. Conclusions DRG2 and p53 expressions play an important role in prostate cancer cell lines treated with docetaxel, and DRG2 levels can predict the response to PARP inhibitors.